Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Prostate Cancer

  Free Subscription


12.03.2018

1 Am J Clin Oncol
6 Anticancer Res
2 BJU Int
1 BMC Cancer
2 BMC Urol
1 Br J Cancer
1 Br J Radiol
1 Cancer
1 Cancer Res
5 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Clin Oncol
2 J Magn Reson Imaging
1 J Natl Med Assoc
2 J Nucl Med
1 J Surg Oncol
2 J Urol
3 JAMA
3 Nat Rev Urol
1 Oncogene
2 Oncology
1 PLoS One
5 Prostate
1 Urol Int
3 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. J BLEDSOE T, S Park H, E Rutter C, Aneja S, et al
    Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States.
    Am J Clin Oncol. 2018 Mar 7. doi: 10.1097/COC.0000000000000423.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. GUO J, Yang J, Zhang X, Feng X, et al
    A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.
    Anticancer Res. 2018;38:1471-1477.
    PubMed     Text format     Abstract available

  3. VALERIANI M, Bonfili P, Reverberi C, Marinelli L, et al
    Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term Outcomes.
    Anticancer Res. 2018;38:1671-1676.
    PubMed     Text format     Abstract available

  4. LINNEY H, Barrett S
    Stereotactic Body Radiation Therapy for Patients with Early-stage Prostate Cancer.
    Anticancer Res. 2018;38:1231-1240.
    PubMed     Text format     Abstract available

  5. ZUGOR V, VON Brandenstein M, Akbarov I, Porres D, et al
    Preoperative Stating of Pelvic Lymph Nodes in Prostate Cancer Patients via Endorectal Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:1763-1765.
    PubMed     Text format     Abstract available

  6. SIEPE G, Buwenge M, Nguyen NP, Macchia G, et al
    Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review.
    Anticancer Res. 2018;38:1221-1230.
    PubMed     Text format     Abstract available

  7. KANEKO S, Sato C, Shiozawa N, Sato A, et al
    Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells.
    Anticancer Res. 2018;38:1391-1399.
    PubMed     Text format     Abstract available


    BJU Int

  8. CHAO M, Ho H, Chan Y, Tan A, et al
    Prospective analysis of hydrogel spacer for prostate cancer patients undergoing radiotherapy.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14192.
    PubMed     Text format     Abstract available

  9. VIDAL AC, Howard LE, de Hoedt A, Kane CJ, et al
    Obese Castration-Resistant Prostate Cancer Patients may be at a lower risk of all-cause mortality: Results from the SEARCH Database.
    BJU Int. 2018 Mar 9. doi: 10.1111/bju.14193.
    PubMed     Text format     Abstract available


    BMC Cancer

  10. CARAM MEV, Estes JP, Griggs JJ, Lin P, et al
    Temporal and geographic variation in the systemic treatment of advanced prostate cancer.
    BMC Cancer. 2018;18:258.
    PubMed     Text format     Abstract available


    BMC Urol

  11. CAO L, Zhang S, Jia CM, He W, et al
    Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies.
    BMC Urol. 2018;18:17.
    PubMed     Text format     Abstract available

  12. SHAO N, Ma G, Zhang J, Zhu W, et al
    miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer.
    BMC Urol. 2018;18:14.
    PubMed     Text format     Abstract available


    Br J Cancer

  13. MIKROPOULOS C, Hutten Selkirk CG, Saya S, Bancroft E, et al
    Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    Br J Cancer. 2018 Mar 6. pii: bjc201811. doi: 10.1038/bjc.2018.
    PubMed     Text format     Abstract available


    Br J Radiol

  14. JUNG SI, Jeon HJ, Park HS, Yu MH, et al
    Multiparametric MR imaging of peripheral zone prostate cancer: effect of postbiopsy hemorrhage on cancer detection according to Gleason score and tumour volume.
    Br J Radiol. 2018 Mar 9:20180001. doi: 10.1259/bjr.20180001.
    PubMed     Text format     Abstract available


    Cancer

  15. DALL'ERA MA, Lo MJ, Chen J, Cress R, et al
    Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31285.
    PubMed     Text format     Abstract available


    Cancer Res

  16. YU-LEE LY, Yu G, Lee YC, Lin SC, et al
    Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway.
    Cancer Res. 2018 Mar 7. pii: 0008-5472.CAN-17-1051.
    PubMed     Text format     Abstract available


    Eur Urol

  17. SJOBERG DD, Vickers AJ, Assel M, Dahlin A, et al
    Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Eur Urol. 2018 Mar 5. pii: S0302-2838(18)30126.
    PubMed     Text format     Abstract available

  18. MANDEL P, Preisser F, Graefen M, Steuber T, et al
    High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy.
    Eur Urol. 2017;71:848-850.
    PubMed     Text format     Abstract available

  19. HEESAKKERS J, Farag F, Bauer RM, Sandhu J, et al
    Pathophysiology and Contributing Factors in Postprostatectomy Incontinence: A Review.
    Eur Urol. 2017;71:936-944.
    PubMed     Text format     Abstract available

  20. MEHRA N, Dolling D, Sumanasuriya S, Christova R, et al
    Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Eur Urol. 2018 Feb 27. pii: S0302-2838(18)30120.
    PubMed     Text format     Abstract available

  21. TYSON MD 2ND, Koyama T, Lee D, Hoffman KE, et al
    Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Eur Urol. 2018 Feb 28. pii: S0302-2838(18)30119.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  22. GRAFF P, Portalez D, Lusque A, Brun T, et al
    IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Feb 2. pii: S0360-3016(18)30180.
    PubMed     Text format     Abstract available


    Int J Urol

  23. HAKARIYA T, Shida Y, Tsurusaki T, Watanabe J, et al
    Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Mar 8. doi: 10.1111/iju.13542.
    PubMed     Text format     Abstract available


    J Clin Oncol

  24. MORGANS AK, Chen YH, Sweeney CJ, Jarrard DF, et al
    Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Clin Oncol. 2018 Mar 9:JCO2017753335. doi: 10.1200/JCO.2017.75.3335.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  25. LUZURIER A, Jouve De Guibert PH, Allera A, Feldman SF, et al
    Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience.
    J Magn Reson Imaging. 2018 Mar 8. doi: 10.1002/jmri.25991.
    PubMed     Text format     Abstract available

  26. PARK JJ, Park BK
    Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treatment according to PRIAS.
    J Magn Reson Imaging. 2016 Oct 26. doi: 10.1002/jmri.25534.
    PubMed     Text format     Abstract available


    J Natl Med Assoc

  27. PERCY-LAURRY A, Altekruse SF, Hossain MB, O'Keefe AM, et al
    Association Between Socioeconomic Status and Tumor Grade Among Black Men with Prostate Cancer.
    J Natl Med Assoc. 2018;110:53-57.
    PubMed     Text format     Abstract available


    J Nucl Med

  28. WONDERGEM M, van der Zant F, Vlottes P, Knol R, et al
    Effects of fasting on (18)F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake.
    J Nucl Med. 2018 Mar 1. pii: jnumed.117.207316. doi: 10.2967/jnumed.117.207316.
    PubMed     Text format     Abstract available

  29. CALAIS J, Fendler WP, Herrmann K, Eiber M, et al
    Reply: Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective trial is on its way.
    J Nucl Med. 2018 Mar 1. pii: jnumed.118.209965. doi: 10.2967/jnumed.118.209965.
    PubMed     Text format    


    J Surg Oncol

  30. VENTIMIGLIA E, Folkvaljon Y, Carlsson S, Bratt O, et al
    Nationwide, population-based study of post radical prostatectomy urinary incontinence correction surgery.
    J Surg Oncol. 2018;117:321-327.
    PubMed     Text format     Abstract available


    J Urol

  31. VAN STAM MA, Pieterse AH, van der Poel HG, Bosch JLHR, et al
    Shared Decision-Making in Prostate Cancer Care: Encouraging every patient to be actively involved in decision-making, or ensuring patients' preferred level of involvement?
    J Urol. 2018 Feb 28. pii: S0022-5347(18)42403.
    PubMed     Text format     Abstract available

  32. PATEL N, Halpern JA, Kasabwala K, Cricco-Lizza E, et al
    Multiple regions of interest on multi-parametric magnetic resonance imaging are not associated with increased detection of clinically significant prostate cancer on fusion biopsy.
    J Urol. 2018 Mar 5. pii: S0022-5347(18)42470-6. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    JAMA

  33. MARTIN RM, Donovan JL, Turner EL, Metcalfe C, et al
    Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    JAMA. 2018;319:883-895.
    PubMed     Text format     Abstract available

  34. BARRY MJ
    Screening for Prostate Cancer: Is the Third Trial the Charm?
    JAMA. 2018;319:868-869.
    PubMed     Text format    

  35. KISHAN AU, Cook RR, Ciezki JP, Ross AE, et al
    Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    JAMA. 2018;319:896-905.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  36. KELSEY R
    Prostate cancer: Mouse model for testing treatments.
    Nat Rev Urol. 2018 Mar 6. pii: nrurol.2018.35. doi: 10.1038/nrurol.2018.
    PubMed     Text format    

  37. HILLE C, Pantel K
    Prostate cancer: Circulating tumour cells in prostate cancer.
    Nat Rev Urol. 2018 Mar 6. pii: nrurol.2018.25. doi: 10.1038/nrurol.2018.
    PubMed     Text format    

  38. KELSEY R
    Prostate cancer: Molecular lymph node analysis for prognostication.
    Nat Rev Urol. 2018 Mar 6. pii: nrurol.2018.33. doi: 10.1038/nrurol.2018.
    PubMed     Text format    


    Oncogene

  39. CHENG Y, Gao XH, Li XJ, Cao QH, et al
    Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway.
    Oncogene. 2018 Mar 8. pii: 10.1038/s41388-018-0177.
    PubMed     Text format     Abstract available


    Oncology

  40. CICERO G, De Luca R, Dieli F
    Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer.
    Oncology. 2017 Sep 6. doi: 10.1159/000479112.
    PubMed     Text format     Abstract available

  41. FENG LR, Espina A, Saligan LN
    Association of Fatigue Intensification with Cognitive Impairment during Radiation Therapy for Prostate Cancer.
    Oncology. 2018 Mar 7. pii: 000487081. doi: 10.1159/000487081.
    PubMed     Text format     Abstract available


    PLoS One

  42. EGGER S, Hughes S, Smith DP, Chambers S, et al
    Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors.
    PLoS One. 2018;13:e0193686.
    PubMed     Text format     Abstract available


    Prostate

  43. OKEGAWA T, Ninomiya N, Masuda K, Nakamura Y, et al
    AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Prostate. 2018 Mar 5. doi: 10.1002/pros.23501.
    PubMed     Text format     Abstract available

  44. HAYMAN J, Phillips R, Chen D, Perin J, et al
    Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23507.
    PubMed     Text format     Abstract available

  45. KEAM SP, Gulati T, Gamell C, Caramia F, et al
    Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23500.
    PubMed     Text format     Abstract available

  46. CARLETON NM, Zhu G, Gorbounov M, Miller MC, et al
    PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23499.
    PubMed     Text format     Abstract available

  47. WU Y, Yu H, Zheng SL, Na R, et al
    A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
    Prostate. 2018 Mar 9. doi: 10.1002/pros.23505.
    PubMed     Text format     Abstract available


    Urol Int

  48. BRUENDL J, Rothbauer C, Ludwig B, Dotzler B, et al
    Accordance of Online Health Information on Prostate Cancer with the European Association of Urology Guidelines.
    Urol Int. 2018 Mar 7. pii: 000487146. doi: 10.1159/000487146.
    PubMed     Text format     Abstract available


    Urology

  49. BORHAN W, Epstein JI
    Significance of Gleason Score 7 With Tertiary Pattern 5 at Radical Prostatectomy.
    Urology. 2017;100:175-179.
    PubMed     Text format     Abstract available

  50. KOMINSKY HD, Bashline M, Eun D, Pontari MA, et al
    Use of Age and Medical Comorbidity to Assess Long-term Other-cause Mortality Risk in a Cohort of Men Undergoing Prostate Biopsy at an Academic Medical Center.
    Urology. 2017;100:169-174.
    PubMed     Text format     Abstract available

  51. JOHNSON SC, Packiam VT, Golan S, Cohen AJ, et al
    The Effect of Obesity on Perioperative Outcomes for Open and Minimally Invasive Prostatectomy.
    Urology. 2017;100:111-116.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: